Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Other Operating Expenses (2018 - 2025)

10x Genomics (TXG) has disclosed Other Operating Expenses for 6 consecutive years, with -$40.7 million as the latest value for Q2 2025.

  • Quarterly Other Operating Expenses changed N/A to -$40.7 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$49.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$49.9 million for FY2025, N/A changed from the prior year.
  • Other Operating Expenses hit -$40.7 million in Q2 2025 for 10x Genomics, down from -$9.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $41.4 million in Q3 2023 to a low of -$40.7 million in Q2 2025.
  • Historically, Other Operating Expenses has averaged $1.7 million across 3 years, with a median of -$330000.0 in 2021.
  • Biggest YoY gain for Other Operating Expenses was 37.09% in 2021; the steepest drop was 363.98% in 2021.
  • Year by year, Other Operating Expenses stood at -$850000.0 in 2021, then skyrocketed by 2403.29% to $19.6 million in 2023, then crashed by 307.89% to -$40.7 million in 2025.
  • Business Quant data shows Other Operating Expenses for TXG at -$40.7 million in Q2 2025, -$9.2 million in Q1 2025, and $19.6 million in Q4 2023.